AI assistant
Vimta Labs Ltd. Investor Presentation 2026
61730_rns_2026-05-06_22249e89-d4c9-424b-9f6e-5df2d41546b9.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Vimta
Driven by Quality. Inspired by Science.
Vimta Labs Limited
Registered Office:
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T: +91 4027264141
F: +91 40 2726 3657
VLL\SE\009\2026-27
Date: 06.05.2026
| BSE Limited,
P J Towers, Dalal Street,
Mumbai: 400001.
Scrip Code No.524394 | National Stock Exchange of India Limited,
“Exchange Plaza”, Bandra,
Kurla Complex, Bandra (E), Mumbai – 400051.
Trading Symbol: VIMTALABS |
| --- | --- |
Dear Sir/Madam,
Sub: Investor Presentation – Q4 Results – FY 2025-26
Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) we are enclosing herewith the Investor Presentation. Further, in terms of to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., https://vimta.com/investor-presentation/
This is for your information and necessary records.
For VIMTA LABS LIMITED
SUJANI
VASIREDDI
Digitally signed by
SUJANI VASIREDDI
Date: 2026.05.06
16:22:06 +05'30'
Sujani Vasireddi
Company Secretary & Compliance Officer
Plot No.5, Life Sciences Campus, Neovantage Science & Technology Park Private Limited, Shamirpet, Genome Valley, Turkapally, Medchal- Malkajgiri, Hyderabad - 500 101, Telangana, India
T: +91 40 6740 4040 Email: [email protected], Website URL: www.vimta.com
CIN: L24110TG1990PLC011977
Vimta*
Driven by Quality. Inspired by Science.
INVESTOR PRESENTATION
Q4 & FY26
Disclaimer
The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.
This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.
No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.
Vimta
Driven by Quality, Inspired by Science.
Table Of Contents
- Q4 & FY26 Earnings
- Company Overview
- Industry Landscape
- Our Competitive Advantage
- Way Forward
Section
01
Q4 & FY26 Earnings
- Q4 & FY26 Highlights
- Key Metrics: Q4 & FY26
- Profit & Loss Statement
- Financial Track Record
- Shareholding Pattern
Q4 FY26 Highlights
5
FY26 Highlights
*Including Exceptional Item
**Cash and Cash equivalents includes other bank balances
6
Key Metrics: Q4 FY26
Key Metrics: FY26
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
*FY25 EPS Adjusted due to issue of Bonus shares
Profit & Loss Statement
| Particulars (₹ Mn) | Q4 FY26 | Q3 FY26 | QoQ(%) | Q4 FY25 | YoY (%) | FY26 | FY25 | YoY (%) |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,092 | 986 | 944 | 4,073 | 3,440 | |||
| Other Income | 28 | 18 | 16 | 90 | 42 | |||
| Total Income | 1,120 | 1,005 | 11.5% | 961 | 16.6% | 4,163 | 3,482 | 19.5% |
| Material and Testing Costs | 224 | 193 | 182 | 807 | 710 | |||
| Cost of lab setup | 0 | 1 | 0 | 1 | 4 | |||
| Changes in inventories of work-in-progress | - | - | - | - | - | |||
| Employee benefits expense | 296 | 284 | 273 | 1,144 | 970 | |||
| Other expenses | 178 | 166 | 160 | 706 | 536 | |||
| Total Expenses | 699 | 644 | 614 | 2,658 | 2,220 | |||
| Exceptional Item | 16 | 16 | ||||||
| EBIDTA | 421 | 344 | 22.3% | 347 | 21.5% | 1,489 | 1,262 | 18.0% |
| EBIDTA (%) | 37.6% | 34.3% | 36.1% | 35.8% | 36.2% | |||
| Finance costs | 3 | 2 | 4 | 12 | 19 | |||
| Depreciation expense | 128 | 109 | 92 | 438 | 353 | |||
| PBT | 290 | 234 | 24.3% | 250 | 16.1% | 1,040 | 890 | 16.8% |
| PBT (%) | 25.9% | 23.3% | 26.0% | 25.0% | 25.6% | |||
| Tax | 79 | 58 | 67 | 264 | 222 | |||
| PAT | 211 | 176 | 20.1% | 183 | 15.2% | 775 | 668 | 16.1% |
| PAT (%) | 18.9% | 17.5% | 19.1% | 18.6% | 19.2% | |||
| Basic EPS (INR) | 4.7 | 4.0 | 19.6% | 4.1 | 15.3% | 17.4 | 15.0 | 15.9% |
- Exceptional Item: Statutory impact of new Labour Codes
Financial Track Record
TOTAL INCOME (₹ Mn)
PROFITABILITY (₹ Mn)
BALANCE SHEET RATIOS
RoE (%)
RoCE (%)
Debt to Equity
Total Capex
- Financial numbers for the period FY24 & FY25 are from continuing operations which exclude Diagnostic and Pathological services business
- CAGR for the period FY20-FY26
10
Shareholding Pattern
Shareholding as on 31st March 2026
| Share Information as on 31st March 2026 | |
|---|---|
| NSE Ticker | VIMTALABS |
| BSE Ticker | 524394 |
| Market Cap (INR Cr) | 1,701.01 |
| % free-float | 64.15% |
| Free-float market cap (INR Cr) | 1,091.20 |
| Total Debt (INR Mn) | 33.3 |
| Cash & Cash Equivalents (INR Mn)** | 650.6 |
| Shares Outstanding | 4,46,69,355 |
| 3M ADTV (Shares)* | 2,42,931.67 |
| 3M ADTV (INR Cr)* | 11.39 |
| Industry | TIC |
*Source: NSE & BSE
**Cash and Cash equivalents includes other bank balances
11
12
Section
02
Company Overview
- Vimta at a Glance
- Our Journey
- Our Offerings
- Geographical Presence
- Management
Vimta at a Glance
Established in 1984, VIMTA is one of India's most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company's broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and environment testing.
42+ Years
Of experience in CRTO industry
1,300+
Dedicated Multi-Disciplinary Team
600,000+
Sq. Ft. of Ultra-modern lab spaces
10
Labs and Offices across India
~100
Successful Regulatory Audits
13
Our Journey
| Infrastructure | People | Investment | Capabilities | Revenues | |
|---|---|---|---|---|---|
| 2024 | 600,000+ ft² | 1300+ | 492 M | Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing | 3,223 M |
| 2015 | 400,000+ ft² | 1000+ | 580 M | Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing | 1,073 M |
| 2006 | 200,000+ ft² | 600+ | 992 M | Clinical Research; Environment; Analytical Testing – Food & Pharma | 542 M |
| 1992 | 50,000+ ft² | 150+ | 85 M | Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research | 16 M |
| 1984 | 500 ft² | 6 | 200,000 | Minerals & ores; Metals; Rice bran oil testing | 156,000 |
- Investment & Revenues in INR
- Investments depicted may have spread across more than the denoted year
Our offerings
Vimta
Driven by Quality. Inspired by Science.
Food & Agri Testing
Electronics & Electricals Testing
Environment Testing & Consultancy
15
1. Drug discovery and development services
| Offerings | Pharma Analytical | Clinical Research | Preclinical Research |
|---|---|---|---|
| Industry | Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health | Pharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality Chemicals | |
| Accreditations & Regulatory Approvals | DCA, USFDA, WHO, EMA, DRAs of Ukraine, Turkey | CDSCO, USFDA, WHO, MHRA, NPRA, and European DRAs | OECD-GLP, CCSEA, DSIR, AAALAC |
| Services | Wide range of analytical services | ||
| · E&L studies | |||
| · Stability testing | |||
| · Method development | |||
| · Validations | |||
| · Genotoxic impurities | |||
| · Elemental analysis | |||
| · In vitro studies | |||
| · Physical Characterisation | |||
| · Dissolution Testing | · Microbiology | ||
| · Immunogenicity studies | |||
| · Characterization | |||
| · Bioassays | · Comprehensive in vitro, ex vivo and in vivo studies | ||
| · ADME, and PK | |||
| · IND enabling packages (genetic toxicology, safety pharmacology, general toxicology, & toxicokinetic studies). | |||
| · Chronic toxicology, reproductive toxicology, neurotoxicology, immunotoxicology, and carcinogenicity | |||
| · Biowaiver and alternative to animal studies | |||
| · Ecotoxicology, environmental fate and metabolism studies |
2. Food & Agri Testing
| Industry | Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed |
|---|---|
| No. of Locations | 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) |
| Accreditations & Regulatory Approvals | • FSSAI, ISO 17025, BIS, APEDA, EIC, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board |
| • Hyderabad Lab is a National Reference Lab for Water & Beverages Testing | |
| • Mumbai Lab is a National Food Laboratory, operated for FSSAI | |
| Services | • Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for all agri, food, food products, water and beverages |
| • New product development support, validations | |
| • Shelf-life assessments | |
| • Packaging material testing | |
| • Nutraceuticals testing, method validations | |
| • Animal feed analysis | |
| • Argo-chemical (crop sciences): support for research and development, method development, validation and testing for regulatory submissions in India, Europe, South America, Japan, Southeast Asia |
17
3. Electricals & Electronics Testing & Certification
| Industry | Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries |
|---|---|
| No. of Locations | 1 (Hyderabad) |
| Accreditations & Regulatory Approvals | · ISO 17025, TEC |
| · BIS & NABCB | |
| Services | · EMI/EMC testing |
| · Radio Frequency testing | |
| · Environmental & reliability testing | |
| · Mechanical & electrical safety testing | |
| · Performance testing | |
| · Product Certification | |
| · CE marking |
18
4. Environment Testing & Consultancy Services
| Industry | Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. |
|---|---|
| No. of Locations | 4 (Hyderabad, Chennai, Kolkata and Noida) |
| Accreditations & Regulatory Approvals | • MoEF, ISO 17025, QCI/NABET, OSHAS 45000 |
| Services | • Post project monitoring |
| • Industrial hygiene & Indoor air | |
| • Advanced testing & tailor-made services (CEMS validation, PG for pollution equipment, Dioxins, Furans, Industrial Gas, VOC as per LEED and EPA) | |
| • Offshore monitoring | |
| • SIA & hydrogeological studies | |
| • EHS audits, Hazardous waste study, Life cycle assessment | |
| • Due diligence studies | |
| • Green audit, Metrological studies | |
| • Noise, air, traffic modelling etc. |
19
Geographical Presence
20
Key Management Team
S P Vasireddi
Executive Chairman
- Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.
- Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.
Harita Vasireddi
Managing Director
- Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.
- Her Core competencies include management & driving organizational adaptability and development, quality management systems, and risk management.
- She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India
Sreenivas Neerukonda
Executive Director
- Sreenivas's core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal-oriented performance.
- He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.
Harriman Vungal
Executive Director - Operations
- Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.
- He has led the Company's effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.
- He holds D. Tech in Electronics from Toronto, Canada.
Siva Kambhampati
Chief Financial Officer
- Siva is a seasoned finance professional with a strong academic foundation. He is a CA and secured 63rd rank in cost accountancy. With over 16 years on experience in the engineering and pharmaceutical industries, he brings diverse expertise in strategic financial planning & management, product costing & pricing, and treasury management.
He has previously worked at Artson engineering Ltd. (A TATA Enterprise, Hyderabad as a CFO.
22
Section
03
Industry Landscape
- Market Opportunity
- Factors Driving Industry Growth
Markets Opportunity (Global)
Pharmaceutical Analytical Testing
Global (USD Mn)
Preclinical
Food Testing
Elevations Testing
23
Markets Opportunity (Indian)
Pharmaceutical Analytical Testing
Indian (USD Mn)
Preclinical
Food Testing
Environment Testing
Electronics Testing
24
Factors Driving Industry Growth
- Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry
-
Specialized knowledge, skills and testing tools that CROs can provide
-
Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third-party inspection & testing
Drug Discovery & Development
Electrical & Electronics Testing
- Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives
- Green push by Government for electrical vehicles
Food Testing
Environment Testing
- Increase in regulations to address the growing concerns of air, water and soil contamination
25
26
Section
04
Our Competitive Advantage
- Our Position in the CRTO Landscape
- Our Strength
Our Position in the CRTO Landscape
Pharma Analytical
-
1 in India
- Customers – 90% of India top 20
- 36% revenues from overseas
Clinical Research
- Among the most reputed CROs in India
- 75% of revenues from overseas
Electronics & Electricals
- One of the leading labs in Southern India
Food Testing
-
1 in India
- Serving 7 of India’s top 10 food companies
- The only private EU commission approved lab in India
Preclinical
- Amongst Top 5 in India
Environment
- Among top 5 in India
- Customers – PSUs, large corporations across industries
27
Our Strengths
Infrastructure
Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium
Customer Centricity
Long term partnerships with customers
Innovations
Continuous addition of services and evolving excellence
Compliance
Strong culture of quality and compliance
Long & successful regulatory track record – cGMP, GLP, GCP
Knowledge
Multi-disciplinary, knowledgeable, skilled and trained manpower
Technology
Wide range of state-of-the-art technologies and scalable capacities
29
Section
05
Way Forward
- Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies
| Favourable markets | Core business strategies | Core operational strategies | Best practices |
|---|---|---|---|
| ✓ Growth momentum in markets | |||
| ✓ Growing demand for safe & quality - drugs, food, diagnostics, electronics & clean environment | ✓ Capacity expansions | ||
| ✓ Service innovations | |||
| ✓ Penetration into new markets | |||
| ✓ Customer partnerships | ✓ Operational excellence | ||
| ✓ Hiring right talent | |||
| ✓ Quality & compliance culture | |||
| ✓ Cutting edge technologies | ✓ Good corporate governance | ||
| ✓ Risk management | |||
| ✓ Listening to customers' needs | |||
| ✓ Continuous learning |
THANK YOU
Vimta Labs Ltd.
Siva Kambhampati | Chief Financial Officer
[email protected]
Ernst & Young
Siddesh Chawan
Advait Bhadekar
[email protected]
[email protected]
Registered Office
142, IDA Phase 2 Cherlapally,
Hyderabad Telangana, India. 500051
NSE: VIMTALABS
ISIN: INE579C01029
BSE: 524394
Website: www.vimta.com
Vimta
When by Guilty Implied by Science.
31